Tirzepatide is a synthetic fatty-acid-conjugated long-acting peptide that simultaneously activates the GIP and GLP-1 receptors — a "twincretin" first-in-class mechanism developed by Eli Lilly. It is among the most thoroughly clinically characterised incretin compounds, with a published research base spanning glycaemic control in type 2 diabetes (SURPASS), body-weight management (SURMOUNT), MASH, obstructive sleep apnoea, and cardiovascular outcomes — making it the most-studied dual agonist available as a research-grade peptide.
Tirzepatide is a 39-amino-acid synthetic peptide engineered to act as a balanced co-agonist of two structurally related class B G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). A C20 fatty diacid moiety conjugated at lysine 20 binds non-covalently to albumin, extending the molecule's circulatory half-life to approximately five days and supporting once-weekly subcutaneous dosing protocols studied in published research.
The GLP-1 arm reproduces the well-characterised incretin response — glucose-dependent insulin secretion from pancreatic β-cells, suppression of glucagon, delayed gastric emptying, and engagement of hypothalamic and brainstem satiety circuits. The GIP arm, historically considered the lesser incretin, contributes complementary insulinotropic activity and is studied for direct effects on adipose-tissue insulin sensitivity, lipid handling and possibly central appetite regulation. The functional synergy of the two pathways underpins Tirzepatide's larger glycaemic and weight-loss effect sizes versus selective GLP-1 monoagonists studied in head-to-head trials.
Importantly, Tirzepatide is engineered with biased agonism at GLP-1R — its signalling is preferentially weighted toward cAMP/PKA activation with reduced β-arrestin recruitment compared with native GLP-1 — which is one of several proposed explanations for its differentiated tolerability and efficacy profile.
The SURPASS trials (SURPASS-1 through SURPASS-5) studied Tirzepatide in adults with type 2 diabetes and consistently reported HbA1c reductions of approximately 1.9–2.6%, with greater than 50% of participants achieving HbA1c <5.7% at the highest dose — outcomes that exceeded the comparator GLP-1 monoagonist (semaglutide 1 mg) on head-to-head endpoints (SURPASS-2, NEJM 2021).
The SURMOUNT obesity programme (SURMOUNT-1, NEJM 2022) reported mean weight reductions of approximately 22.5% at the 15 mg dose over 72 weeks in adults with obesity — a magnitude not previously achieved by any pharmacological intervention. Follow-on trials in MASH (SYNERGY-NASH), obstructive sleep apnoea (SURMOUNT-OSA), and cardiovascular outcomes (SURPASS-CVOT, SURMOUNT-MMO) have either reported or are continuing to read out. Tirzepatide holds FDA approval as Mounjaro (T2D) and Zepbound (obesity); regulatory status of the research-grade peptide form differs by jurisdiction.
Across SURPASS-1 through SURPASS-5, Tirzepatide produced HbA1c reductions of approximately 1.9–2.6% in adults with type 2 diabetes, with strong dose-response across the 5 mg, 10 mg and 15 mg cohorts. SURPASS-2 (NEJM, 2021) demonstrated superiority over semaglutide 1 mg on glycaemic, weight and lipid endpoints — establishing the clinical advantage of dual versus single incretin agonism.
Fasting glucose, postprandial glucose excursion, and HOMA-IR insulin-resistance indices were each improved alongside the HbA1c effect. The glucose-dependent mechanism of GLP-1R-driven insulin secretion means clinically meaningful hypoglycaemia is uncommon as monotherapy in research protocols.
SURMOUNT-1 (NEJM, 2022) — 72 weeks, 2539 adults with obesity — reported mean weight reduction of approximately 22.5% at the 15 mg dose vs 3.1% with placebo. The dose-response curve was clean and continued to slope downward through study end, suggesting incomplete plateau at 72 weeks. SURMOUNT-3 demonstrated additional weight loss when Tirzepatide was added on top of an initial intensive lifestyle intervention.
DXA substudies have characterised the fat-mass vs lean-mass change profile, with the majority of weight lost being adipose tissue. Substantial reductions in visceral adipose, waist circumference, blood pressure, triglycerides, and CRP were reported alongside the weight-loss endpoint.